The role of airway stent placement in the management of tracheobronchial stenosis caused by inoperable advanced lung cancer

Surgery Today ◽  
2010 ◽  
Vol 40 (4) ◽  
pp. 315-320 ◽  
Author(s):  
Kinya Furukawa ◽  
Junzo Ishida ◽  
Gaku Yamaguchi ◽  
Jitsuo Usuda ◽  
Hidemitsu Tsutsui ◽  
...  
Keyword(s):  
Lung Cancer ◽  
Stent Placement ◽  
Advanced Lung Cancer ◽  
Tracheobronchial Stenosis ◽  
Airway Stent

scholarly journals C4-02: The role of airway stent placement in the management of tracheobronchial stenosis due to inoperable advanced lung cancer

2007 ◽  
Vol 2 (8) ◽  
pp. S368-S369
Author(s):  
Kinya Furukawa ◽  
Junzo Ishida ◽  
Gaku Yamaguchi ◽  
Hidemitsu Tsutsui ◽  
Makoto Saito ◽  
...  
Keyword(s):  
Lung Cancer ◽  
Stent Placement ◽  
Advanced Lung Cancer ◽  
Tracheobronchial Stenosis ◽  
Airway Stent

scholarly journals The Role of Malnutrition and Muscle Wasting in Advanced Lung Cancer

2020 ◽  
Vol 22 (6) ◽  
Author(s):  
Rishi Jain ◽  
Chris Coss ◽  
Peter Whooley ◽  
Mitch Phelps ◽  
Dwight H. Owen
Keyword(s):  
Lung Cancer ◽  
Muscle Wasting ◽  
Advanced Lung Cancer

scholarly journals Role of PARP1-mediated autophagy in EGFR-TKI resistance in non-small cell lung cancer

2020 ◽  
Vol 10 (1) ◽  
Author(s):  
Zhimin Zhang ◽  
Xiaojuan Lian ◽  
Wei Xie ◽  
Jin Quan ◽  
Maojun Liao ◽  
...  
Keyword(s):  
Lung Cancer ◽  
Kinase Inhibitors ◽  
Growth Factor Receptor ◽  
Advanced Lung Cancer ◽  
Tki Resistance ◽  
Geo Dataset ◽  
Epidermal Growth

AbstractResistance to epidermal growth factor receptor-tyrosine kinase inhibitors (EGFR-TKIs) has become the main clinical challenge of advanced lung cancer. This research aimed to explore the role of PARP1-mediated autophagy in the progression of TKI therapy. PARP1-mediated autophagy was evaluated in vitro by CCK-8 assay, clonogenic assay, immunofluorescence, and western blot in the HCC-827, H1975, and H1299 cells treated with icotinib (Ico), rapamycin, and AZD2281 (olaparib) alone or in combination. Our results and GEO dataset analysis confirmed that PARP1 is expressed at lower levels in TKI-sensitive cells than in TKI-resistant cells. Low PARP1 expression and high p62 expression were associated with good outcomes among patients with NSCLC after TKI therapy. AZD2281 and a lysosomal inhibitor reversed resistance to Ico by decreasing PARP1 and LC3 in cells, but an mTOR inhibitor did not decrease Ico resistance. The combination of AZD2281 and Ico exerted a markedly enhanced antitumor effect by reducing PARP1 expression and autophagy in vivo. Knockdown of PARP1 expression reversed the resistance to TKI by the mTOR/Akt/autophagy pathway in HCC-827IR, H1975, and H1299 cells. PARP1-mediated autophagy is a key pathway for TKI resistance in NSCLC cells that participates in the resistance to TKIs. Olaparib may serve as a novel method to overcome the resistance to TKIs.

PD-1 Blockade in Early-Stage Lung Cancer

2019 ◽  
Vol 70 (1) ◽  
pp. 425-435 ◽  
Author(s):  
Samuel Rosner ◽  
Joshua E. Reuss ◽  
Patrick M. Forde
Keyword(s):  
Lung Cancer ◽  
Early Stage ◽  
Immune Checkpoint Blockade ◽  
Advanced Lung Cancer ◽  
Early Stage Lung Cancer ◽  
Early Results ◽  
Stage Disease ◽  
Relapse Rates ◽  
Stage Lung Cancer

Early-stage non–small cell lung cancer is a potentially curable disease, but with relapse rates exceeding 50% with standard treatments, this is a patient population in critical need of therapy innovation. Immunotherapy with immune checkpoint blockade has revolutionized the treatment strategy for advanced lung cancer. However, the role of this therapy in earlier-stage disease is largely unknown. The study of immunotherapy in earlier-stage disease has many advantages, including assessment of pathologic response and incorporation of translational scientific analyses to evaluate antitumor immune responses. Multiple clinical trials are currently under way, with promising early results.

scholarly journals Role of the clinical nurse specialist as a non-medical prescriber in managing the palliative care needs of individuals with advanced lung cancer

2021 ◽  
Vol 27 (4) ◽  
pp. 205-212
Author(s):  
Jenny Osborne ◽  
Helen Kerr
Keyword(s):  
Lung Cancer ◽  
Palliative Care ◽  
Positive Impact ◽  
Clinical Nurse Specialist ◽  
Advanced Lung Cancer ◽  
Nurse Specialist ◽  
Care Needs ◽  
Clinical Nurse ◽  
Palliative Care Needs

Background: Rapid identification of the palliative care needs of individuals with a diagnosis of advanced lung cancer is crucial to maximise the patient's quality of life by upholding exemplary standards of patient-centred holistic care. The clinical nurse specialist is in an ideal position to contribute to the identification and management of the palliative care needs of individuals with advanced lung cancer through the assessment and timely prescribing of medications to manage distressing symptoms. Aim: This paper reviews and critiques the role of the clinical nurse specialist as an independent non-medical prescriber in the management of palliative symptoms in end-of-life care for patients with advanced lung cancer. Results: Published literature highlights the positive impact the clinical nurse specialist has as a non-medical prescriber in addressing the palliative needs of individuals with lung cancer. However, there are barriers and challenges, and to overcome these, maximising resources and the availability of support is required to ensure the delivery of timely, person-centred care. Conclusion: The clinical nurse specialist as a non-medical prescriber is an evolving role. There are a range of factors that may influence the clinical nurse specialist to confidently and competently undertake this role. These include the perception that there will be an escalation in the workload, concerns about increased accountability and inadequate mentoring for this new role. To incentivise this role, multidisciplinary support is essential in promoting the clinical nurse specialist's confidence for developing this service to individuals with advanced lung cancer.

scholarly journals The role of palliative care in the management of patients with lung cancer

2020 ◽  
Vol 9 (4) ◽  
pp. LMT39
Author(s):  
Irena Tan ◽  
Kavitha Ramchandran
Keyword(s):  
Lung Cancer ◽  
Palliative Care ◽  
Clinical Judgment ◽  
Patient Reported Outcomes ◽  
Symptom Burden ◽  
Advanced Lung Cancer ◽  
Patient Reported ◽  
Patient Prognosis

Palliative care (PC) is the care of patients and their families with serious illness and is rapidly becoming an important part of the care of cancer patients. Patients with advanced lung cancer are a highly symptomatic population of patients and clearly experience benefits in quality of life and potentially benefits in overall survival when PC is incorporated early on after diagnosis. However, referrals to PC are still reliant on clinical judgment of patient prognosis and symptom burden. Moving forward, improving the integration of PC and lung cancer care will require more efficient real-time screening of patient symptoms, which may be accomplished through the use of patient-reported outcomes.

Sign in / Sign up

Export Citation Format

Share Document